Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

nce, noted, "The early data from our antiviral program designed to test the potential of our PS-targeting antibodies to prevent and treat viral hemorrhagic fevers is very encouraging, and we are pleased to have the opportunity to present our findings at this major meeting of our biodefense peers. Results to date are confirming that our PS-targeting antibodies may have broad spectrum potential against multiple viruses, which could make them valuable against both hemorrhagic fever viruses and other biodefense threats. Further efficacy studies are already underway and we look forward to reporting on our progress as we continue to advance this important program."

Researchers also reported that studies are in progress to determine the pharmacokinetics and efficacy of PS-targeting antibodies in additional VHF infection models, as well as to develop lyophilized formulations suitable for an extended shelf life under a variety of storage and shipping conditions. In addition, Peregrine is developing a second-generation, fully human PS-targeting antibody as part of its federally funded antiviral program efforts.

"These positive initial efficacy data after administration of only a single dose is an early confirmation of the potential of our anti-PS antibodies as broad-spectrum therapeutics for VHF," said Steven W. King, president and CEO of Peregrine. "They also reflect the excellent progress being achieved by our multi-institutional project team. This first public presentation of data from our ongoing federally funded program is also consistent with our extensive preclinical and clinical experience showing the broad-spectrum antiviral potential of our PS-targeting technology platform and we look forward to sharing more results from the studies as further progress is made."

Under a major biodefense initiative, bavituximab and a fully human equivalent antibody are in preclinical development for the treatment of viral hemorrhagic fevers un
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... the delivery of product safety and pharmacovigilance services and software tools to pharmaceutical ... application, PRIMO Mobile by Allergan Japan. PRIMO Mobile is a mobile data intake ...
(Date:9/3/2015)... - bioLytical Laboratories Inc., a leader in rapid diagnostic ... of a rapid point of care assay for early ... HIV gp41 IgM antibodies " has been published in ... ability to detect early HIV infection.  ... annual International AIDS Society Conference, which highlighted early ...
(Date:9/3/2015)... ... September 03, 2015 , ... If you plan to attend the ... October, you will also want to sign up for the tour of Framingham State ... tour includes a walk through of the (8) chemistry teaching labs that are exclusively ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biochips and Microarrays ... offering. This report is an analysis ... The report starts with a description of technologies ... include array comparative genomic hybridization (CGH), copy number ...
Breaking Biology Technology:November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... SAN RAMON, Calif., Aug. 7 Odyssey Thera, ... from Pfizer Inc, following,Pfizer,s decision to progress a ... candidate was extensively studied by,Odyssey Thera as part ... are very pleased with the progress of the ...
... 7 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (OTC Bulletin Board: CHBT), ... manufacture, marketing and distribution of,probiotics dietary supplements, today ... a.m. EDT on Friday, August 15, 2008, to ... ended June 30, 2008, of its fiscal,2009., ...
... SCOLR Pharma, Inc.,(Amex: DDD ) today reported ... 30, 2008. The Company will host a live conference ... Time)., Daniel O. Wilds, SCOLR Pharma,s President and ... during the second quarter,maintaining a sharp focus on advancing ...
Cached Biology Technology:China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results 2China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results 7
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Arabia Biomedical Sensors market is estimated at $0.23 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... For nearly half a century, scientists have been trying ... reasonably sized X-ray laser that could, among other things, ... decades, University of Colorado at Boulder physics professors Margaret ... that goal. Recent breakthroughs by their team at ...
... arrhythmia a chronic irregularity of heartbeat which ... the condition is not acutely life-threatening, it does increase ... cardiac insufficiency, stroke and dementia. In the third of ... of researchers, led by LMU physician PD Dr. Stefan ...
... world,s population will swell to 9 billion people by ... to provide enough food to meet demand, says University ... Branen, a University of Idaho food scientist, organized a ... Science annual meeting Sunday to explore ways biotechnology could ...
Cached Biology News:CU physicists use ultra-fast lasers to open doors to new technologies unheard of just years ago 2CU physicists use ultra-fast lasers to open doors to new technologies unheard of just years ago 3When the heart gets out of step 2When the heart gets out of step 3Biotech, nanotech and synthetic biology roles in future food supply explored 2
... Sciences provides a comprehensive kinase analysis ... substrate (PKS) peptide microarrays synthesized on ... kinase profiling, quantitative measurement of kinase ... This comprehensive service includes preparation of ...
... NH2-terminal kinase) signal transduction cascade is ... pathways in mammals. JNK pathway activation ... is associated with the nuclear accumulation ... in the immune response, cellular proliferation, ...
... ProteomeLab PA 800 is an automated, ... of Beckman Coulters ProteomeLab family of ... comprehensive range of automated protein characterization ... mapping, isoelectric focusing, carbohydrate profiling and ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: